Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Erasca, Inc. (ERAS : NSDQ)
 
 • Company Description   
Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN DIEGO.

Number of Employees: 103

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.44 Daily Weekly Monthly
20 Day Moving Average: 1,241,760 shares
Shares Outstanding: 283.29 (millions)
Market Capitalization: $407.93 (millions)
Beta: 1.05
52 Week High: $3.45
52 Week Low: $1.01
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.28% -13.25%
12 Week 35.21% 13.44%
Year To Date -42.63% -46.26%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3115 MERRYFIELD ROW SUITE 300
-
SAN DIEGO,CA 92121
USA
ph: 858-465-6511
fax: -
ir@erasca.com http://www.erasca.com
 
 • General Corporate Information   
Officers
Jonathan E. Lim - Chief Executive Officer; Chairman and Co-Founder
David M. Chacko - Chief Financial Officer and Chief Business Officer
Michael D. Varney - Chair of Research and Development and Director
James A. Bristol - Director
Alexander W. Casdin - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29479A108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/11/25
Share - Related Items
Shares Outstanding: 283.29
Most Recent Split Date: (:1)
Beta: 1.05
Market Capitalization: $407.93 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.50 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.02
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 52.17%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -36.56
12/31/24 - -40.09
ROA
06/30/25 - -
03/31/25 - -31.08
12/31/24 - -33.55
Current Ratio
06/30/25 - -
03/31/25 - 12.35
12/31/24 - 9.84
Quick Ratio
06/30/25 - -
03/31/25 - 12.35
12/31/24 - 9.84
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 1.41
12/31/24 - 1.50
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©